Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM...
-
Upload
shaylee-haidle -
Category
Documents
-
view
220 -
download
3
Transcript of Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM...
![Page 1: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/1.jpg)
Electrophysiology 2011
Taresh Taneja, MD, FACC
Assistant Professor of Medicine
Texas A & M HSC COM
Scott & White Hospital
![Page 2: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/2.jpg)
![Page 3: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/3.jpg)
“The more things change, the more they stay the same.”
Jean-Baptiste Alphonse Karr
![Page 4: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/4.jpg)
EP 2011
Sudden Cardiac Death Cardiac Resynchronization Therapy Syncope Atrial Fibrillation
![Page 5: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/5.jpg)
Case Vignette
• A 74-year-old man with a history of hypertension and myocardial infarction that occurred 5 years previously presents with breathlessness on exertion.
• His current medications include a statin and aspirin.• On examination, his pulse is 76 beats per minute and
regular, and his blood pressure is 121/74 mm Hg.• There is jugular venous distention, lateral displacement of
the apex beat, and edema in his lower limbs.• The lung examination is normal.• An echocardiogram shows left ventricular dilatation, globally
reduced contractility, and an ejection fraction of 33%.• How should his case be managed?
![Page 6: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/6.jpg)
Pathophysiology of Systolic Heart Failure
McMurray J. N Engl J Med 2010;362:228-238
![Page 7: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/7.jpg)
Clinical Classifications of Heart Failure Severity
McMurray J. N Engl J Med 2010;362:228-238
![Page 8: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/8.jpg)
Treatment Algorithm for Systolic Heart Failure
McMurray J. N Engl J Med 2010;362:228-238
![Page 9: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/9.jpg)
Telemetry Strip Showing Pause-Independent Polymorphic Ventricular Tachycardia.
Britton KA et al. N Engl J Med 2010;362:1721-1726.
![Page 10: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/10.jpg)
Sudden Cardiac Death (SCD)
Death from unexpected circulatory arrest, usually due to cardiac arrhythmia
occurring within an hour of the onset of symptoms.
Sudden Cardiac Arrest (SCA)- Episode of resuscitated SCD
![Page 11: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/11.jpg)
Sudden Cardiac Death
Estimates range 200,000 - 450, 000 SCD’s annually depending on the definition used.
13% of all natural deaths are SCD using the 1 hour definition.
50% of all CHD deaths are sudden. Overall incidence of SCD 1 to 2/1000
population.
![Page 12: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/12.jpg)
![Page 13: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/13.jpg)
36 cc
![Page 14: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/14.jpg)
Implantable Cardioverter Defibrillator (ICD)
Secondary Prevention- Multiple studies have shown a 50% relative-risk reduction in arrhythmic death and a 25% relative-
risk reduction in all-cause mortality.
Patients who die once are more likely to die again.
![Page 15: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/15.jpg)
Primary Prevention of SCD
• Patients with a history of myocardial infarction and a reduced ejection fraction are at increased risk for life-threatening ventricular arrhythmias.
• Which of these patients are the most appropriate candidates for implantable cardioverter–defibrillator (ICD) therapy is unclear.
![Page 16: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/16.jpg)
Summary of Major Randomized Trials of ICD Therapy for Primary Prevention of Sudden Death after
Myocardial Infarction
Myerburg R. N Engl J Med 2008;359:2245-2253
![Page 17: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/17.jpg)
Amiodarone or an Implantable Cardioverter-Defibrillator for Congestive Heart Failure
Gust H. Bardy, M.D., Kerry L. Lee, Ph.D., Daniel B. Mark, M.D., Jeanne E. Poole, M.D., Douglas L. Packer, M.D., Robin Boineau, M.D., Michael Domanski, M.D.,
Charles Troutman, R.N., Jill Anderson, R.N., George Johnson, B.S.E.E., Steven E. McNulty, M.S., Nancy Clapp-Channing, R.N., M.P.H., Linda D. Davidson-Ray, M.A., Elizabeth S. Fraulo, R.N., Daniel P. Fishbein, M.D., Richard M. Luceri, M.D., John H.
Ip, M.D. and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators
N Engl J MedVolume 352;3:225-237
January 20, 2005
![Page 18: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/18.jpg)
Study Overview This placebo-controlled study compared the effect
of amiodarone and an implantable cardioverter-defibrillator (ICD) on mortality in patients with New York Heart Association class II or III congestive heart failure (CHF)
Amiodarone had no benefit overall and slightly increased mortality among patients with class III CHF
ICD therapy reduced mortality overall, but the benefit appeared to be restricted to patients with class II CHF
These important results will broaden the use of ICD therapy
![Page 19: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/19.jpg)
SCD-HeFT Protocol
DCM + CAD and CHF
Placebo N = 847 ICD Implant N = 829
Minimum of 2.5 years follow-up required
45 months average follow-up Optimized B, ACE-I, Diuretics
Amiodarone N = 845
EF < 35%
NYHA Class II or III
6-Minute Walk, Holter
R 2521 Patients
Bardy GH. N Engl J Med. 2005;352:225-237.
![Page 20: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/20.jpg)
Kaplan-Meier Estimates of Death from Any Cause
Bardy, G. et al. N Engl J Med 2005;352:225-237
![Page 21: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/21.jpg)
Kaplan-Meier Estimates of Death from Any Cause for the Prespecified Subgroups of Ischemic CHF (Panel A)
and Nonischemic CHF (Panel B)
Bardy, G. et al. N Engl J Med 2005;352:225-237
![Page 22: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/22.jpg)
Kaplan-Meier Estimates of Death from Any Cause for the Prespecified Subgroups of NYHA Class II (Panel A)
and Class III (Panel B)
Bardy, G. et al. N Engl J Med 2005;352:225-237
![Page 23: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/23.jpg)
Hazard Ratios for the Comparison of Amiodarone and ICD Therapy with Placebo in Various Subgroups of Interest
Bardy, G. et al. N Engl J Med 2005;352:225-237
![Page 24: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/24.jpg)
Conclusions In patients with NYHA class II or III CHF
and LVEF of 35 percent or less, amiodarone has no favorable effect on survival, whereas single-lead, shock-only ICD therapy reduces overall mortality by 23 percent
![Page 25: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/25.jpg)
Incremental Cost-EffectivenessCardiovascular Interventions
HypertensionTherapy(diastolic95 - 104mmHg)
Expensive
BorderlineCost-Effective
Cost-Effective
HighlyCost-Effective
Incr
emen
tal
Co
st p
er L
ife-
Yea
r S
aved
EconomicallyUnattractive
Lovastatin(chol. =
290 mg/dL,50 yrs old,
male, no riskfactors)
PTCA(chronic CAD,severe angina
1 VD)
CABG(chronic
CADmild angina,
3 VD)
End Stage Renal
Disease Treatment
Exercise SPECT (atypical
angina who can walk
on treadmill)
RoutineCoronary
Angiography(35 - 84 yrs
old, low risk MI,has CHF)
$8,461$17,701
$40,750
$67,000
$135,000
$150,000
Carotid Disease
Screening(65 yrs old,
male, no
symptoms)
$200,000
$120,000
![Page 26: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/26.jpg)
Incremental Cost-Effectiveness ICD, CRT, and CRT-D Therapies
COMPANIONCRT-D1
Incr
emen
tal
Co
st p
er L
ife-
Yea
r S
aved
COMPANIONCRT1
MADIT-IIICD3
AVIDICD4
$28,000 $38,200
$50,000$67,000
Expensive
BorderlineCost-Effective
Cost-Effective
HighlyCost-Effective
EconomicallyUnattractive
SCD-HeFTICD2
$33,000
1 Feldman AM. www.theheart.org. ACC News. March 16, 2005.2 Mark DB. www.theheart.org. AHA News. November 11, 2004.3 Ak-Khatib S. Ann Intern Med. 2005;142:593-600.4 Larsen G. Circulation. 2002;105:2049-2057.
![Page 27: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/27.jpg)
Original Article Defibrillator Implantation Early after Myocardial
Infarction
Gerhard Steinbeck, M.D., Dietrich Andresen, M.D., Karlheinz Seidl, M.D., Johannes Brachmann, M.D., Ellen Hoffmann, M.D., Dariusz Wojciechowski, M.D., Zdzisława
Kornacewicz-Jach, M.D., Beata Sredniawa, M.D., Géza Lupkovics, M.D., Franz Hofgärtner, M.D., Andrzej Lubinski, M.D., Mårten Rosenqvist, M.D., Alphonsus
Habets, Ph.D., Karl Wegscheider, Ph.D., Jochen Senges, M.D., for the IRIS Investigators
N Engl J MedVolume 361(15):1427-1436
October 8, 2009
![Page 28: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/28.jpg)
Study Overview
• Implantation of a defibrillator early after myocardial infarction (MI) in high-risk patients reduced the risk of sudden cardiac death, but there was a reciprocal increase in the risk of nonsudden cardiac death
• Overall mortality was not affected by early defibrillator implantation, and therefore this intervention cannot be recommended after MI in high-risk patients
![Page 29: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/29.jpg)
Baseline Demographic and Clinical Characteristics of the Patients, According to Study Group
Steinbeck G et al. N Engl J Med 2009;361:1427-1436
![Page 30: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/30.jpg)
Cumulative Risk of Death from Any Cause According to Study Group
Steinbeck G et al. N Engl J Med 2009;361:1427-1436
![Page 31: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/31.jpg)
Cumulative Risk of Cardiac Death, According to Study Group
Steinbeck G et al. N Engl J Med 2009;361:1427-1436
![Page 32: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/32.jpg)
Conclusion
Prophylactic ICD therapy did not reduce overall mortality among patients with acute myocardial infarction and clinical features
that placed them at increased risk
![Page 33: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/33.jpg)
ICD implantation Post Acute MI
Acute MI-Sudden Cardiac Death paradox firmly established
SCD post-MI may not be due to arrhythmia alone
Potential deleterious effect of ICD implantation and testing
?
![Page 34: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/34.jpg)
Sudden cardiac death after myocardial infarction in patients with type 2 diabetes
M. Juhani Junttila, MD, Petra Barthel, MD, Robert J. Myerburg, MD, Timo H. Mäkikallio, MD, Axel Bauer, MD, Kurt Ulm, PhD, Antti Kiviniemi, PhD, Mikko Tulppo, PhD, Juha S.
Perkiömäki, MD, Georg Schmidt, MD and Heikki V. Huikuri, MD
Heart RhythmVolume 7, Issue 10, Pages 1396-1403 (October 2010)
DOI: 10.1016/j.hrthm.2010.07.031
![Page 35: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/35.jpg)
Sudden cardiac death after myocardial infarction in patients with type 2 diabetes
Study population included enrollees in two prospective post-MI studies: Multiple Risk Factor Analysis Trial and Improved Stratification of Autonomic Regulation for Risk Prediction postinfarction survey program.
3276 acute MI patients Diabetic vs Non Diabetic patients: Mean Age
64 vs 59 years, 32 vs 22% females, LVEF 49% vs 52, 3 vs CAD 42 vs 30%
![Page 36: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/36.jpg)
Figure 1
![Page 37: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/37.jpg)
Figure 2
![Page 38: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/38.jpg)
Aggregate National Experience With the Wearable Cardioverter-Defibrillator: Event Rates, Compliance,
and SurvivalChung et al. JACC. 2010;56;194
3,569 patients
Indications: ICD explants (23.4%), VT/VF (16.1%), LVEF ≤ 35% with Recent MI (12.5%), Post-CABG (8.9%),
Nonischemic CM (20.0%), and LVEF> 35% with recent MI (3.8%)
![Page 39: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/39.jpg)
![Page 40: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/40.jpg)
Copyright ©2010 American College of Cardiology Foundation. Restrictions may apply.
Chung, M. K. et al. J Am Coll Cardiol 2010;56:194-203
Actual WCD Use
![Page 41: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/41.jpg)
Copyright ©2010 American College of Cardiology Foundation. Restrictions may apply.
Chung, M. K. et al. J Am Coll Cardiol 2010;56:194-203
Events While Wearing the WCDAggregate National Experience With the Wearable
Cardioverter-Defibrillator
![Page 42: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/42.jpg)
Original Article An Entirely Subcutaneous Implantable
Cardioverter-Defibrillator
Gust H. Bardy, M.D., Warren M. Smith, M.B., Margaret A. Hood, M.B., Ian G. Crozier, M.B., Iain C. Melton, M.B., Luc Jordaens, M.D., Ph.D., Dominic Theuns,
Ph.D., Robert E. Park, M.B., David J. Wright, M.D., Derek T. Connelly, M.D., Simon P. Fynn, M.D., Francis D. Murgatroyd, M.D., Johannes Sperzel, M.D., Jörg Neuzner, M.D., Stefan G. Spitzer, M.D., Andrey V. Ardashev, M.D., Ph.D., Amo Oduro, M.B.,
B.S., Lucas Boersma, M.D., Ph.D., Alexander H. Maass, M.D., Isabelle C. Van Gelder, M.D., Ph.D., Arthur A. Wilde, M.D., Ph.D., Pascal F. van Dessel, M.D., Reinoud E. Knops, M.D., Craig S. Barr, M.B., Pierpaolo Lupo, M.D., Riccardo
Cappato, M.D., and Andrew A. Grace, M.B., Ph.D.
N Engl J MedVolume 363(1):36-44
July 1, 2010
![Page 43: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/43.jpg)
Locations of the Components of a Subcutaneous Implantable Cardioverter-Defibrillator In Situ
Bardy GH et al. N Engl J Med 2010;363:36-44
![Page 44: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/44.jpg)
Chest Radiographs and an Electrocardiogram in a Patient Who Underwent Placement and Testing of a Subcutaneous
Implantable Cardioverter-Defibrillator (ICD)
Bardy GH et al. N Engl J Med 2010;363:36-44
![Page 45: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/45.jpg)
Cardiac Resynchronization Therapy
![Page 46: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/46.jpg)
Case Vignette A 55-year-old man who had had an anterior-wall
myocardial infarction six months previously is admitted with an exacerbation of congestive heart failure.
An electrocardiogram shows sinus rhythm with a left bundle-branch block; an echocardiogram demonstrates a left ventricular ejection fraction of 25 percent.
He is treated with furosemide, lisinopril, and carvedilol. However, during an office visit three months later, he
reports persistent shortness of breath with mild exertion. He is referred to a cardiologist, who recommends
implantation of a biventricular pacemaker.
![Page 47: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/47.jpg)
The Cardiac Conduction System and Biventricular Pacing
Jarcho J. N Engl J Med 2006;355:288-294
![Page 48: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/48.jpg)
The Cardiac Conduction System and Biventricular Pacing
In patients with a LBBB, conduction of the wave of depolarization in the left ventricle is
markedly altered, proceeding from the anterior septum through the left ventricular
myocardium to the inferior and lateral left ventricular walls- left ventricular contraction is dyssynchronous, mechanically inefficient with decreases in left ventricular ejection farction
and cardiac output.
![Page 49: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/49.jpg)
![Page 50: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/50.jpg)
CRT- The Evidence
Trial Patie-nts
Age (yrs)
LVEF CAD QRS (ms)
LBB MR▼
Meta-Analysis
1,634 63-66 21-23% 37-69% 158-176 54-87% 23%
COMPANION 1,520 65 22% 56% 158 71% 24%
![Page 51: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/51.jpg)
1520 patients, NYHA III/ IV, QRS 120 ms, EF 35% RANDOMIZED
Optimal medical therapy vs. OMT + cardiac resynchronization pacemaker vs. OMT + cardiac resynchronization defibrillator
![Page 52: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/52.jpg)
![Page 53: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/53.jpg)
CRT Indications
Class I- EF ≤ 35%, QRS ≥ 0.12 sec, SR, NYHA III/ Ambulatory Class IV + OMT- CRT±ICD
Class IIA- EF ≤ 35%, QRS ≥ 0.12 sec, AF, NYHA III/ Ambulatory Class IV + OMT- CRT±ICD
![Page 54: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/54.jpg)
Original Article Cardiac-Resynchronization Therapy for the
Prevention of Heart-Failure Events
Arthur J. Moss, M.D., W. Jackson Hall, Ph.D., David S. Cannom, M.D., Helmut Klein, M.D., Mary W. Brown, M.S., James P. Daubert, M.D., N.A. Mark Estes, III, M.D.,
Elyse Foster, M.D., Henry Greenberg, M.D., Steven L. Higgins, M.D., Marc A. Pfeffer, M.D., Ph.D., Scott D. Solomon, M.D., David Wilber, M.D., Wojciech Zareba,
M.D., Ph.D., for the MADIT-CRT Trial Investigators
N Engl J MedVolume 361(14):1329-1338
October 1, 2009
![Page 55: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/55.jpg)
Kaplan-Meier Estimates of the Probability of Survival Free of Heart Failure
Moss AJ et al. N Engl J Med 2009;361:1329-1338
![Page 56: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/56.jpg)
Conclusion
CRT combined with ICD decreased the risk of heart-failure events in relatively
asymptomatic patients with a low ejection fraction and wide
QRS complex
![Page 57: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/57.jpg)
MADIT-CRTEditorial- Mariell Jessup, MD
CRT benefit solely driven by a 41% reduction in risk of first heart failure event, since mortality not influenced.
In CRT trials with symptomatic patients, 29 patients need to be treated for 6 months, 13 patients for 2 years and 9 patients for 3 years to prevent 1 death.
MADIT CRT enrolled patients with stage C and NOT stage B (truly asymptomatic).
MADIT CRT- treat 12 patients to prevent 1 heart failure hospitalization
![Page 58: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/58.jpg)
Cardiac Resynchronization- Effect of Bundle Branch Block
Analyzed the results of MADIT-CRT 1820 patients, NYHA I/II, LVEF≤ 30%, QRS
≥130 ms, on optimal medical therapy 1281 LBBB, 228 RBBB, 308 IVCD Hazard ratios for the primary end-point of
death or heart failure event were significantly lower in the LBBB patients than in the non-LBBB patient.
Zareba et al. JACC 2011
![Page 59: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/59.jpg)
Cardiac Resynchronization In Hypertrophic Obstructive Cardiomyopathy
Biventricular pacing was attempted in 12 severely symptomatic HOCM patients and was successful in 9 patients.
Functional capacity and QOL improved NYHA class decreased from 3.2±0.4 at
baseline to 1.4±0.5 at 1 year with a reduction in the LV gradient from 74±23 mmHg at baseline to 28±17 mmHg at 1 year.
Berruezo et al. Heart Rhythm 2011
![Page 60: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/60.jpg)
US Registry of Sudden Death in Athletes
Healthy young competitive athletes assembled over 27 years, 1,866 died suddenly (or survived cardiac arrest).
Sudden death were due to cardiovascular disease in 56% and 82% occurred with physical exertion.
HCM – 36% and congenital coronary anomalies- 17%
Pre-participation screening with history, PE and EKG did not impact the rate of sudden death.
Maron et al. Circ. 2009;119:1085
![Page 61: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/61.jpg)
US Registry of Sudden Death in Athletes
![Page 62: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/62.jpg)
US Registry of Sudden Death in Athletes
![Page 63: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/63.jpg)
Pathophysiology of Commotio Cordis
Maron B, Estes N. N Engl J Med 2010;362:917-927
![Page 64: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/64.jpg)
Syncope
Transient loss of consciousness due to transient global cerebral hypoperfusion characterized by rapid onset, short duration, and spontaneous
complete recovery.
![Page 65: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/65.jpg)
www.escardio.org/guidelines
![Page 66: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/66.jpg)
![Page 67: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/67.jpg)
www.escardio.org/guidelines
![Page 68: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/68.jpg)
www.escardio.org/guidelines
![Page 69: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/69.jpg)
www.escardio.org/guidelines
![Page 70: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/70.jpg)
Original Article Lenient versus Strict Rate Control in Patients with
Atrial Fibrillation
Isabelle C. Van Gelder, M.D., Hessel F. Groenveld, M.D., Harry J.G.M. Crijns, M.D., Ype S. Tuininga, M.D., Jan G.P. Tijssen, Ph.D., A. Marco Alings, M.D., Hans L.
Hillege, M.D., Johanna A. Bergsma-Kadijk, M.Sc., Jan H. Cornel, M.D., Otto Kamp, M.D., Raymond Tukkie, M.D., Hans A. Bosker, M.D., Dirk J. Van Veldhuisen, M.D.,
Maarten P. Van den Berg, M.D., for the RACE II Investigators
N Engl J MedVolume 362(15):1363-1373
April 15, 2010
![Page 71: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/71.jpg)
Study Overview
• This clinical trial of outcomes in patients with atrial fibrillation showed that lenient rate control (resting heart rate, <110 beats per minute) was not inferior to strict rate control (resting heart rate, <80 beats per minute)
• On the basis of the results, strict rate control may be abandoned as a therapeutic strategy in many patients with permanent atrial fibrillation
![Page 72: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/72.jpg)
Cumulative Incidence of the Composite Primary Outcome and Its Components during the 3-Year Follow-up Period, According to Treatment Group
Van Gelder IC et al. N Engl J Med 2010;362:1363-1373
![Page 73: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/73.jpg)
Kaplan-Meier Estimates of the Cumulative Incidence of the Primary Outcome, According to Treatment Group
Van Gelder IC et al. N Engl J Med 2010;362:1363-1373
![Page 74: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/74.jpg)
Conclusion
• In patients with permanent atrial fibrillation, lenient rate control is as effective as strict rate control and is easier to achieve
![Page 75: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/75.jpg)
Thromboemblic Risk in Atrial Fibrillation
![Page 76: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/76.jpg)
www.escardio.org/guidelines
![Page 77: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/77.jpg)
www.escardio.org/guidelines
![Page 78: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/78.jpg)
www.escardio.org/guidelines
![Page 79: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/79.jpg)
www.escardio.org/guidelines
![Page 80: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/80.jpg)
www.escardio.org/guidelines
![Page 81: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/81.jpg)
AF guidelines update 2011-Dabigatran
Class I Dabigatran is useful as an alternative to warfarin
for the prevention of stroke and systemic thromboembolism in patients with paroxysmal to persistent AF and risk factors for stroke or systemic embolization who do not have a prosthetic heart valve or hemodynamically significant valve disease, severe renal failure (creatinine clearance < 15 ml/min) or advanced liver disease (impaired baseline clotting function). Level of evidence B
![Page 82: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/82.jpg)
www.escardio.org/guidelines
![Page 83: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/83.jpg)
Catheter ABlation versus ANtiarrhythmic Drug Therapy in Atrial Fibrillation (CABANA) Trial
Mayo Clinic Rochester Duke Clinical Research Institute
National Heart Lung and Blood Institute
![Page 84: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/84.jpg)
Future of AF--ATRIA StudyProjected Number of Adults with AF in the U.S.
Go et al: JAMA 285:2370, 2001Go et al: JAMA 285:2370, 2001
MillionsMillions
YearYear
Upper scenarios based onsensitivity analysesLower scenarios based onsensitivity analyses
Upper scenarios based onsensitivity analysesLower scenarios based onsensitivity analyses
![Page 85: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/85.jpg)
Impact of Atrial Fibrillation on Mortality in Framingham Study
Benjamin et al: Circ 98:946, 1998Benjamin et al: Circ 98:946, 1998
75-94 Years Old75-94 Years Old
Follow-up (yr)Follow-up (yr)
0
20
40
60
80
0 1 2 3 4 5 6 7 8 9 10
Follow-up (yr)Follow-up (yr)
Dea
d (%
)D
ead
(%)
55-74 Years Old55-74 Years Old
Men AFMen AF
Women AFWomen AF
Men no AFMen no AF
Women no AFWomen no AF
![Page 86: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/86.jpg)
CABANA Trial Inclusion CriteriaCABANA Trial Inclusion CriteriaSubjects must meet all of the following criteria
• Have documented AF episodes 1 hour in duration; with 2 episodes over 4 months with ECG documentation of 1 episode or at least 1 episode of AF lasting >1 week
• Warrant active therapy beyond simple ongoing observation
• Be eligible for catheter ablation and 2 sequential rhythm control and/or 3 rate control drugs
• Be 65 yr of age, or <65 yr with 1 of the following risk factors for strokeHypertensionDiabetesCongestive heart failure (including systolic or diastolic heart failure)Prior stroke or TIALA size >5.0 cm (or volume index 40 cc/m2)EF 35
![Page 87: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/87.jpg)
CABANA Trial CABANA Trial Primary Objective and HypothesisPrimary Objective and Hypothesis
The treatment strategy of The treatment strategy of percutaneous left atrial catheter percutaneous left atrial catheter ablation for the purpose of eliminating atrial fibrillation ablation for the purpose of eliminating atrial fibrillation (AF) is superior to current state-of-the-art medical (AF) is superior to current state-of-the-art medical therapy with either rate control or rhythm control drugs therapy with either rate control or rhythm control drugs for reducing total mortality (primary endpoint)for reducing total mortality (primary endpoint) and and decreasing the composite endpoint of total mortality, decreasing the composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest (key disabling stroke, serious bleeding, or cardiac arrest (key secondary endpoint) in patients with untreated or secondary endpoint) in patients with untreated or incompletely treated AF warranting therapyincompletely treated AF warranting therapy
![Page 88: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/88.jpg)
Design of the CABANA StudyDesign of the CABANA StudyAtrial fibrillation
Eligible for ablation and/or drug therapy
65 yr of age
<65 yr w/ 1 CVA risk factor
R
Drug Rx & AC
• Rate control
• Rhythm Rx
1° ablation & AC
• PV isolation
• Adjunctive
Descriptive analysis
• NSR vs AF impact
• w/ w/o heart disease
• AF type – (paroxysmal; persistent; long-standing persistent)
• CT/MR image analysis
• ECG/EGM analysisFollow-up
60 months
![Page 89: Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.](https://reader038.fdocuments.net/reader038/viewer/2022102923/551b762f550346a10a8b4bfd/html5/thumbnails/89.jpg)
CABANA Sites International ApproachCABANA Sites International Approach
CanadaCanada1010
U.SU.S..9090
SouthSouthAmAm55
AsiaAsia55
AustraliaAustraliaNZNZ55
EuropeEurope3030
UKUK1010